Anaptys Announces Participation at Upcoming Investor Conferences

Group 1 - AnaptysBio, Inc. is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [2] - The company's pipeline includes rosnilimab, ANB033, and ANB101, with various trials at different phases [2] - Anaptys has out-licensed therapeutic antibodies, including a PD-1 antagonist to GSK and an IL-36R antagonist to Vanda Pharmaceuticals [2] Group 2 - Anaptys plans to separate its biopharma operations from its royalty assets by year-end 2026, allowing investors to align their investment strategies with each company's objectives [3] - The company will participate in multiple investor conferences, including the Guggenheim Emerging Outlook and the TD Cowen Annual Health Care Conference [1] - Live webcasts of the investor meetings will be available on Anaptys' investor website, with replays accessible for at least 30 days [1]